Health Economics›Urothelial carcinoma›Locally advanced or metastatic disease first-line platinum-ineligible

Locally advanced or metastatic disease first-line platinum-ineligible

Urothelial carcinoma · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	4.0 mo	12.9 mo	2	R 573 911 PFS proxy	2
Atezolizumab monotherapy Variant #01	—	R 31 255	21d	—	15.7 mo	2	R 62 509 PFS proxy	1
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	—	—	7	R 11 705 PFS proxy	1

3 of 3 regimens shown